Analysts forecast that Mediwound Ltd (NASDAQ:MDWD) will report earnings of ($0.19) per share for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Mediwound’s earnings, with the highest EPS estimate coming in at ($0.18) and the lowest estimate coming in at ($0.20). Mediwound reported earnings of ($0.16) per share in the same quarter last year, which would indicate a negative year over year growth rate of 18.8%. The firm is expected to issue its next earnings results on Thursday, November 15th.

According to Zacks, analysts expect that Mediwound will report full year earnings of ($0.71) per share for the current fiscal year, with EPS estimates ranging from ($0.75) to ($0.64). For the next fiscal year, analysts anticipate that the company will report earnings of ($0.72) per share, with EPS estimates ranging from ($0.83) to ($0.65). Zacks’ EPS averages are an average based on a survey of analysts that follow Mediwound.

Mediwound (NASDAQ:MDWD) last posted its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.05. The company had revenue of $1.03 million during the quarter, compared to analysts’ expectations of $0.96 million. Mediwound had a negative net margin of 783.30% and a negative return on equity of 210.90%.

A number of equities analysts have weighed in on MDWD shares. Oppenheimer set a $14.00 price objective on shares of Mediwound and gave the company a “buy” rating in a research report on Monday. Wells Fargo & Co set a $11.00 price objective on shares of Mediwound and gave the company a “buy” rating in a research report on Wednesday, August 8th. ValuEngine raised shares of Mediwound from a “sell” rating to a “hold” rating in a research report on Friday, June 1st. Finally, Zacks Investment Research cut shares of Mediwound from a “hold” rating to a “sell” rating in a research report on Wednesday, July 11th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $9.79.

A number of large investors have recently bought and sold shares of MDWD. Nexthera Capital LP purchased a new position in Mediwound in the 2nd quarter valued at about $308,000. Wells Fargo & Company MN boosted its position in Mediwound by 19.9% in the 1st quarter. Wells Fargo & Company MN now owns 121,323 shares of the biopharmaceutical company’s stock valued at $631,000 after buying an additional 20,134 shares during the last quarter. Renaissance Technologies LLC boosted its position in Mediwound by 10.4% in the 2nd quarter. Renaissance Technologies LLC now owns 130,500 shares of the biopharmaceutical company’s stock valued at $900,000 after buying an additional 12,300 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its position in Mediwound by 1.0% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,098,277 shares of the biopharmaceutical company’s stock valued at $14,478,000 after buying an additional 21,559 shares during the last quarter. 32.13% of the stock is owned by institutional investors.

NASDAQ:MDWD traded up $0.05 on Tuesday, reaching $6.50. The stock had a trading volume of 66,500 shares, compared to its average volume of 37,939. The stock has a market cap of $171.75 million, a P/E ratio of -10.65 and a beta of -0.14. Mediwound has a 12-month low of $3.56 and a 12-month high of $7.35.

Mediwound Company Profile

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.

Featured Article: How much money do you need to begin day trading?

Get a free copy of the Zacks research report on Mediwound (MDWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mediwound (NASDAQ:MDWD)

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.